The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Sponsor content
321 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire, tezepelumab 210 mg in 1.91mL solution for Injection prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire tezepelumab 210 mg in 1.91mL solution for Injection prefilled pen.
-
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
-
-
Australian Public Assessment Report (AusPAR)Truqap (capivasertib), in combination with fulvestrant, was approved for the treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.
-
-
Jan-2025Prescription medicine evaluationActive ingredient: durvalumab.
-
Jan-2025Prescription medicine evaluationActive ingredient: acalabrutinib maleate monohydrate.